Hemoglobin subunit zeta (HBZ)

Hemoglobin subunit zeta is an alpha-like subunit of hemoglobin, specifically expressed during the earliest stages of embryonic development in the human yolk sac[1][2][4][6]. Encoded by the HBZ gene, it is part of the human alpha-globin gene cluster and is replaced by alpha-globin subunits as development progresses past the embryonic stage[1][4][6]. Zeta-globin forms the zeta chain of embryonic hemoglobins, which have higher oxygen affinity compared to adult forms, facilitating oxygen uptake from maternal blood[3][5][7]. HBZ has functional significance primarily during embryogenesis and does not serve as a direct therapeutic or drug target in approved pharmacology or medicine[6]. Defects in the HBZ gene or disruptions in its cluster may contribute to some cases of alpha-thalassemia[6]. Hemoglobin subunit zeta has no known interacting drugs or mechanisms of action relevant to therapeutics, since its biological role is largely developmental and not present in adult physiology[6][10]. There are no established biomarker or safety concern implications for patient selection or therapeutic monitoring for this subunit[6]. The term “hemoglobin subunit zeta” is properly spelled and referenced, and the target listing is accurate in scientific usage[1][4][6].

Other names

Hemoglobin subunit zetaHBZHBZ2HBZ1HBZ-T1HBAZHemoglobin zeta chainZeta-globinhemoglobin zeta chainzeta-globinhemoglobinzeta